• AAPL 169.89
  • TSLA 170.18
  • AMZN 173.67
  • MSFT 399.04
  • INTC 35.11
  • EURUSD 1.0731
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. YMAB.NASDAQ

Y mAbs Therapeutics (YMAB NASDAQ) stock market data APIs

$15.33 0.49(3.3%) as of April 25, 2024

Y mAbs Therapeutics Financial Data Overview

14.84
15.33
-
15.4436
14.28
4.6-20.9
669 M
43 777 K
84 819 K
-0.02
0.759
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'YMAB',
Type: 'Common Stock',
Name: 'Y mAbs Therapeutics',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: NULL,
CIK: '1722964',
EmployerIdNumber: '47-4619612',
FiscalYearEnd: 'December',
IPODate: '2018-09-21',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Y mAbs Therapeutics Fundamental Data is available in our Financial Data APIs

  • Net Revenue 84 819 K
  • EBITDA -20 455 000
  • Earnings Per Share -0.49
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Y mAbs Therapeutics Earnings via APIs

  • Latest Release 2024-03-01
  • EPS/Forecast -0.2

Get Y mAbs Therapeutics End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Y mAbs Therapeutics latest news via APIs

Here's Why We're Not At All Concerned With Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have done very well over the last year, with the share pric...

Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Y-mAbs Therapeutics, Inc NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused...
Do you have any questions?
support@eodhistoricaldata.com